CoChat

Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons.

Open access

The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.

Abstract

Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are characterized by intraneuronal deposition of the nuclear TAR DNA-binding protein 43 (TDP-43) caused by unknown mechanisms. Here, we studied TDP-43 in primary neurons under different stress conditions and found that only proteasome inhibition by MG-132 or lactacystin could induce significant cytoplasmic accumulation of TDP-43, a histopathological hallmark in disease. This cytoplasmic accumulation was accompanied by phosphorylation, ubiquitination and aggregation of TDP-43, recapitulating major features of disease. Proteasome inhibition produced similar effects in both hippocampal and cortical neurons, as well as in immortalized motor neurons. To determine the contribution of TDP-43 to cell death, we reduced TDP-43 expression using small interfering RNA (siRNA), and found that reduced levels of TDP-43 dose-dependently rendered neurons more vulnerable to MG-132. Taken together, our data suggests a role for the proteasome in subcellular localization of TDP-43, and possibly in disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0022850

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Proteasome inhibition results in cytoplasmic TDP-43 accumulation in cultured neurons. (A) Example of immunohistochemical staining for TDP-43 on human frontotemporal lobar degeneration (FTLD) brain and amyotrophic lateral sclerosis (ALS) spinal cord sections. While TDP-43 is normally in the nucleus (asterisk), it accumulates in cytoplasmic aggregates (arrow), while being depleted from the nucleus in affected dentate gyrus neurons in FTLD-TDP. Similarly, TDP-43 that is normally in the nucleus of motor neurons (asterisk), accumulates (arrowhead) and forms cytoplasmic aggregates (arrow) and is depleted from the nucleus in ALS. (B) Primary neurons were treated with vehicle (DMSO) or different substances and then stained with antibodies to TDP-43 to assess its subcellular distribution, and neurofilament (NF) for cellular integrity. Doses and treatment times are specified in Materials and methods. TDP-43 localizes primarily to the nucleus upon treatment with H2O2 (oxidative stress), N-Methyl-D-aspartic acid (NMDA, excitotoxicity), staurosporine (caspase activation), thapsigargin or tunicamycine (both endoplasmic reticulum (ER) stress). In contrast, proteasome inhibition with lactacystin or MG-132 treatment induces cytoplasmic accumulation of TDP-43 (arrowheads). DAPI stains nuclei. Representative neurons from three independent experiments are shown.
Figure 1 Proteasome inhibition results in cytoplasmic TDP-43 accumulation in cultured neurons. (A) Example of immunohistochemical staining for TDP-43 on human frontotemporal lobar degeneration (FTLD) brain and amyotrophic lateral sclerosis (ALS) spinal cord sections. While TDP-43 is normally in the nucleus (asterisk), it accumulates in cytoplasmic aggregates (arrow), while being depleted from the nucleus in affected dentate gyrus neurons in FTLD-TDP. Similarly, TDP-43 that is normally in the nucleus of motor neurons (asterisk), accumulates (arrowhead) and forms cytoplasmic aggregates (arrow) and is depleted from the nucleus in ALS. (B) Primary neurons were treated with vehicle (DMSO) or different substances and then stained with antibodies to TDP-43 to assess its subcellular distribution, and neurofilament (NF) for cellular integrity. Doses and treatment times are specified in Materials and methods. TDP-43 localizes primarily to the nucleus upon treatment with H2O2 (oxidative stress), N-Methyl-D-aspartic acid (NMDA, excitotoxicity), staurosporine (caspase activation), thapsigargin or tunicamycine (both endoplasmic reticulum (ER) stress). In contrast, proteasome inhibition with lactacystin or MG-132 treatment induces cytoplasmic accumulation of TDP-43 (arrowheads). DAPI stains nuclei. Representative neurons from three independent experiments are shown.CC BY · PubMed Central
Figure 2 Proteasome inhibition results in cytoplasmic accumulation of TDP-43, but not hnRNP A1, hnRNP A2/B1 or FUS in primary hippocampal neurons. (A) TDP-43 expression is restricted to the nucleus (broken line) in vehicle (DMSO) treated primary hippocampal neurons, while being absent from the cytoplasm (open arrowhead). Treatment with 5 µM MG-132 for 12 hours, however, results in cytoplasmic accumulation of TDP-43 (arrowhead), together with reduced nuclear staining. The cellular integrity appears similar in vehicle and MG-132 treated cells, as shown by staining for cytoskeletal neurofilament (NF). Cell nuclei are counterstained with DAPI. Scale bar, 10 µm. (B) Quantification of nuclear and cytoplasmic TDP-43 fluorescence staining of vehicle and MG-132 treated primary hippocampal neurons. MG-132 treatment reduces nuclear TDP-43 (Student's t test P<0.05; * indicates P<0.01), while cytoplasmic TDP-43 increases markedly (** indicates P<0.001). (C) In a subset of neurons, MG-132 induced accumulation of TDP-43 in the cytoplasm is accompanied by focal intensive staining in soma and processes, suggestive of aggregate formation (arrow). Scale bar, 25 µm. (D) While TDP-43 accumulates in the cytoplasm upon MG-132 treatment, the nuclear localization of neither hnRNP A1, hnRNP A2/B1 nor FUS is affected (open arrowhead) compared to vehicle (DMSO) treated neurons. Nuclei are stained with DAPI. Scale bar, 10 µm.
Figure 2 Proteasome inhibition results in cytoplasmic accumulation of TDP-43, but not hnRNP A1, hnRNP A2/B1 or FUS in primary hippocampal neurons. (A) TDP-43 expression is restricted to the nucleus (broken line) in vehicle (DMSO) treated primary hippocampal neurons, while being absent from the cytoplasm (open arrowhead). Treatment with 5 µM MG-132 for 12 hours, however, results in cytoplasmic accumulation of TDP-43 (arrowhead), together with reduced nuclear staining. The cellular integrity appears similar in vehicle and MG-132 treated cells, as shown by staining for cytoskeletal neurofilament (NF). Cell nuclei are counterstained with DAPI. Scale bar, 10 µm. (B) Quantification of nuclear and cytoplasmic TDP-43 fluorescence staining of vehicle and MG-132 treated primary hippocampal neurons. MG-132 treatment reduces nuclear TDP-43 (Student's t test P<0.05; * indicates P<0.01), while cytoplasmic TDP-43 increases markedly (** indicates P<0.001). (C) In a subset of neurons, MG-132 induced accumulation of TDP-43 in the cytoplasm is accompanied by focal intensive staining in soma and processes, suggestive of aggregate formation (arrow). Scale bar, 25 µm. (D) While TDP-43 accumulates in the cytoplasm upon MG-132 treatment, the nuclear localization of neither hnRNP A1, hnRNP A2/B1 nor FUS is affected (open arrowhead) compared to vehicle (DMSO) treated neurons. Nuclei are stained with DAPI. Scale bar, 10 µm.CC BY · PubMed Central
Figure 3 Cell death occurrs after TDP-43 alterations in MG-132 treated primary neurons. (A) Staining for neuronal β3-tubulin is similar in vehicle (DMSO) and MG-132-treated neurons after 12 hours, whereas after 36 hours of treatment the staining reveals fragmentation of tubulin in MG-132 treated cells, indicating cell death. Scale bar, 50 µM. Representative pictures from at least three experiments are shown. (B) Number of viable attached primary neurons are similar for up to 24 hours of vehicle and MG-132 treatment, but decline significantly thereafter upon MG-132 exposure (* indicates P<0.05; n = 4). (C) Immunocytochemical staining with antibodies to TDP-43 combined with propidium iodine (PI) and nuclear counterstaining with DAPI. Cell death is indicated by PI uptake and nuclear staining (arrowheads). Note the cytoplasmic accumulation of TDP-43 upon MG-132 treatment (right panels), and the increased numbers of PI positive neurons after 36 hours of MG-132 exposure (bottom right panel). Scale bar, 25 µM. (D) Numbers of PI positive neurons are similar after 16 hours of vehicle and MG-132, and 36 h of vehicle treatment, but significantly increased after 36 hours of MG-132 exposure (Student's t test P<0.05; n.s., not significant; * indicates P<0.05).
Figure 3 Cell death occurrs after TDP-43 alterations in MG-132 treated primary neurons. (A) Staining for neuronal β3-tubulin is similar in vehicle (DMSO) and MG-132-treated neurons after 12 hours, whereas after 36 hours of treatment the staining reveals fragmentation of tubulin in MG-132 treated cells, indicating cell death. Scale bar, 50 µM. Representative pictures from at least three experiments are shown. (B) Number of viable attached primary neurons are similar for up to 24 hours of vehicle and MG-132 treatment, but decline significantly thereafter upon MG-132 exposure (* indicates P<0.05; n = 4). (C) Immunocytochemical staining with antibodies to TDP-43 combined with propidium iodine (PI) and nuclear counterstaining with DAPI. Cell death is indicated by PI uptake and nuclear staining (arrowheads). Note the cytoplasmic accumulation of TDP-43 upon MG-132 treatment (right panels), and the increased numbers of PI positive neurons after 36 hours of MG-132 exposure (bottom right panel). Scale bar, 25 µM. (D) Numbers of PI positive neurons are similar after 16 hours of vehicle and MG-132, and 36 h of vehicle treatment, but significantly increased after 36 hours of MG-132 exposure (Student's t test P<0.05; n.s., not significant; * indicates P<0.05).CC BY · PubMed Central
Figure 4 Primary cortical neurons show cytoplasmic accumulation and eventually insolubility of TDP-43 in response to proteasome inhibition. (A) Scheme of subcellular extraction into cytoplasmic and nuclear fractions, with subsequent reconstitution of insoluble proteins in urea buffer. For details see Methods and materials. (B) Western blotting of representative fractionation with nuclear marker hnRNP A1 and cytoplasmic marker Gapdh. (C) Subcellular fractionation of vehicle (DMSO) and MG-132-treated primary cortical neurons over 60 hours. TDP-43 is primarily in the nuclear fraction after 6 to 60 hours of vehicle treatment. In contrast, nuclear TDP-43 decreased progressively, and increased transiently in the cytoplasmic fraction upon MG-132 treatment. (D) Insoluble pellets from the cytoplasmic fraction were extracted with a urea buffer. This shows increasing amounts of insoluble TDP-43 (arrowhead) during MG-132, but not vehicle treatment. Long exposure of the Western blot reveals the presence of both low molecular weight fragments (*) and high molecular weight aggregates (#) of TDP-43 upon MG-132 treatment. Representative blots of three experiments are shown.
Figure 4 Primary cortical neurons show cytoplasmic accumulation and eventually insolubility of TDP-43 in response to proteasome inhibition. (A) Scheme of subcellular extraction into cytoplasmic and nuclear fractions, with subsequent reconstitution of insoluble proteins in urea buffer. For details see Methods and materials. (B) Western blotting of representative fractionation with nuclear marker hnRNP A1 and cytoplasmic marker Gapdh. (C) Subcellular fractionation of vehicle (DMSO) and MG-132-treated primary cortical neurons over 60 hours. TDP-43 is primarily in the nuclear fraction after 6 to 60 hours of vehicle treatment. In contrast, nuclear TDP-43 decreased progressively, and increased transiently in the cytoplasmic fraction upon MG-132 treatment. (D) Insoluble pellets from the cytoplasmic fraction were extracted with a urea buffer. This shows increasing amounts of insoluble TDP-43 (arrowhead) during MG-132, but not vehicle treatment. Long exposure of the Western blot reveals the presence of both low molecular weight fragments (*) and high molecular weight aggregates (#) of TDP-43 upon MG-132 treatment. Representative blots of three experiments are shown.CC BY · PubMed Central
Figure 5 Progressive insolubility of TDP-43 upon proteasome inhibition in primary cortical neurons. (A) Proteins were extracted from MG-132 and vehicle (DMSO) treated primary cortical neurons, with RIPA buffer followed by urea extraction of the insoluble pellets. TDP-43 (arrowhead) and its fragments (*) progressively disappear from the RIPA-soluble fractions over 60 hours, whereas no change is observed in vehicle treated controls. Note the presence of soluble TDP-43 fragments in controls. In parallel, TDP-43 (arrowhead) increased in the insoluble (Urea) fractions of MG-132 treated neurons together with fragments (*) and high molecular weight aggregates (#). An additional TDP-43 reactive band of approximately 50kD appears only in primary cortical neurons. (B) Consistent with proteasome inhibition by MG-132, levels of heat-shock protein 70 (Hsp70) increase with time. (C) Similarly, the amount of insoluble highly ubiquitinated proteins increase progressively upon MG-132 treatment. (D) Immunoprecipitation (IP) with an antibody to TDP-43 and subsequent detection with an antibody to ubiquitin shows the high degree of ubiquitination of the high molecular weight TDP-43 reactive species (#). Note the 50kD Fc-antibody band (α). (E) Antibodies specific to phosphorylation sites on TDP-43 (pS403/404 and pS409/410) reveal increasing phosphorylation of TDP-43 over time upon MG-132 treatment. Representative Western blots from four experiments are shown. (F) Dephosphorylation of urea extracts with alkaline phosphatase (AP) confirms the specificity of the antibodies to S403/4 and S409/10. Lane 1, urea extract of DMSO-treated neurons treated with AP; lane 2, urea fraction of MG-132-treated neurons for 36 hours; lane 3, same extract as lane 2 but treated with AP. (G) Similar to the Western blots, immunocytochemical staining with pS403/404 shows cytoplasmic staining in MG-132-treated neurons, different from DMSO-treated cells.
Figure 5 Progressive insolubility of TDP-43 upon proteasome inhibition in primary cortical neurons. (A) Proteins were extracted from MG-132 and vehicle (DMSO) treated primary cortical neurons, with RIPA buffer followed by urea extraction of the insoluble pellets. TDP-43 (arrowhead) and its fragments (*) progressively disappear from the RIPA-soluble fractions over 60 hours, whereas no change is observed in vehicle treated controls. Note the presence of soluble TDP-43 fragments in controls. In parallel, TDP-43 (arrowhead) increased in the insoluble (Urea) fractions of MG-132 treated neurons together with fragments (*) and high molecular weight aggregates (#). An additional TDP-43 reactive band of approximately 50kD appears only in primary cortical neurons. (B) Consistent with proteasome inhibition by MG-132, levels of heat-shock protein 70 (Hsp70) increase with time. (C) Similarly, the amount of insoluble highly ubiquitinated proteins increase progressively upon MG-132 treatment. (D) Immunoprecipitation (IP) with an antibody to TDP-43 and subsequent detection with an antibody to ubiquitin shows the high degree of ubiquitination of the high molecular weight TDP-43 reactive species (#). Note the 50kD Fc-antibody band (α). (E) Antibodies specific to phosphorylation sites on TDP-43 (pS403/404 and pS409/410) reveal increasing phosphorylation of TDP-43 over time upon MG-132 treatment. Representative Western blots from four experiments are shown. (F) Dephosphorylation of urea extracts with alkaline phosphatase (AP) confirms the specificity of the antibodies to S403/4 and S409/10. Lane 1, urea extract of DMSO-treated neurons treated with AP; lane 2, urea fraction of MG-132-treated neurons for 36 hours; lane 3, same extract as lane 2 but treated with AP. (G) Similar to the Western blots, immunocytochemical staining with pS403/404 shows cytoplasmic staining in MG-132-treated neurons, different from DMSO-treated cells.CC BY · PubMed Central
Figure 6 TDP-43 reduction increased vulnerability of neurons. (A) Immunocytochemistry of nuclear TDP-43 in neurons expressing control (siR co) or two different siRNAs against TDP-43 (siR #543 and siR #560). SiR #543 and more so siR #560 reduce TDP-43 levels. Propidium iodine (PI) uptake indicates increased cell death in siR #560 neurons. DAPI counterstains nuclei. (B) Quantification of TDP-43 fluorescence intensity reveals a 42±5.0% and 88±2.2% reduction of TDP-43 levels with siR #543 and siR #560, respectively, compared to control (siR co) neurons (Student's t test P<0.05; *** indicates P<0.0001). Levels of TDP-43 are similar in siR co and wild-type (WT) neurons (n.s., not significant). (C) Western blotting confirms reduction of TDP-43 levels with siR #543 and siR #560, compared to siR co and wild-type (WT) neurons. Actin serves as loading control. (D) Numbers of PI positive neurons upon treatment with vehicle (DMSO) or MG-132 for 16 hours. Numbers of PI positive cells are similar in DMSO- and MG-132-treated siR co neurons, as well as in DMSO-treated siR #543 cells (Student's t test P<0.05; n.s., not significant). MG-132 treatment significantly increases numbers of PI positive siR #543 neurons (P<0.0001). High numbers of PI positive siR #560 neurons (79±1.5%) are also increased by MG-132, with virtually all cells being PI positive (98±1.4%; *** indicates P<0.0001). (E) MG-132 induces cytoplasmic accumulation (arrowheads) of TDP-43 in both siR co and siR #543 neurons. Note the faint staining in siR #543 neurons due to reduced TDP-43 levels.
Figure 6 TDP-43 reduction increased vulnerability of neurons. (A) Immunocytochemistry of nuclear TDP-43 in neurons expressing control (siR co) or two different siRNAs against TDP-43 (siR #543 and siR #560). SiR #543 and more so siR #560 reduce TDP-43 levels. Propidium iodine (PI) uptake indicates increased cell death in siR #560 neurons. DAPI counterstains nuclei. (B) Quantification of TDP-43 fluorescence intensity reveals a 42±5.0% and 88±2.2% reduction of TDP-43 levels with siR #543 and siR #560, respectively, compared to control (siR co) neurons (Student's t test P<0.05; *** indicates P<0.0001). Levels of TDP-43 are similar in siR co and wild-type (WT) neurons (n.s., not significant). (C) Western blotting confirms reduction of TDP-43 levels with siR #543 and siR #560, compared to siR co and wild-type (WT) neurons. Actin serves as loading control. (D) Numbers of PI positive neurons upon treatment with vehicle (DMSO) or MG-132 for 16 hours. Numbers of PI positive cells are similar in DMSO- and MG-132-treated siR co neurons, as well as in DMSO-treated siR #543 cells (Student's t test P<0.05; n.s., not significant). MG-132 treatment significantly increases numbers of PI positive siR #543 neurons (P<0.0001). High numbers of PI positive siR #560 neurons (79±1.5%) are also increased by MG-132, with virtually all cells being PI positive (98±1.4%; *** indicates P<0.0001). (E) MG-132 induces cytoplasmic accumulation (arrowheads) of TDP-43 in both siR co and siR #543 neurons. Note the faint staining in siR #543 neurons due to reduced TDP-43 levels.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 73 references

Cited by

See all 131

Metadata

Authors
van Eersel, J., Ke, Y. D., Gladbach, A., Bi, M., Götz, J., Kril, J. J., & Ittner, L. M.
Affiliations
The University of Sydney (AU)
Corresponding author
Ittner, Lars M.
Venue
PLoS ONE
Published
2011-07-29
Volume
6
Issue
7
Pages
e22850
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2088821814
Cited by
130
References
73
Citations by year
2026: 15 · 2025: 9 · 2024: 12 · 2023: 9 · 2022: 6 · 2021: 7 · 2020: 8 · 2019: 8 · 2018: 8 · 2017: 5 · 2016: 10 · 2015: 9 · 2014: 9 · 2013: 11 · 2012: 4
FWCI
4.87
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • National Science Council
  • Medical Research Council
  • Australian Research Council
  • National Health and Medical Research Council
Topics
  • Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Keywords
TDP-43, proteasome inhibition, cytoplasmic accumulation, protein aggregation, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, neuronal stress, TDP-43 phosphorylation, ubiquitination, motor neurons, hippocampal neurons, cortical neurons, neurodegeneration
MeSH terms
Animals, Cell Nucleus, Cells, Cultured, Cytoplasm, DNA-Binding Proteins, Humans, Immunoenzyme Techniques, Leupeptins, Neurons, Phosphorylation, RNA, Messenger, Subcellular Fractions, Blotting, Western, Cysteine Proteinase Inhibitors, Cell Death, RNA, Small Interfering, Immunoprecipitation, Mice, Ubiquitination, Proteasome Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. https://app.cochat.ai/papers/10.1371/journal.pone.0022850
The paper
van Eersel, J., Ke, Y. D., Gladbach, A., Bi, M., Götz, J., Kril, J. J., & Ittner, L. M. (2011). Cytoplasmic accumulation and aggregation of TDP-43 upon proteasome inhibition in cultured neurons. PLoS ONE. https://doi.org/10.1371/journal.pone.0022850

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.